Gina M. Capiaux, Ph.D.
|2002||Weill Cornell Medical College, New York, NY, United States|
Mean distance: (not calculated yet)
ParentsSign in to add mentor
ChildrenSign in to add trainee
CollaboratorsSign in to add collaborator
BETA: Related publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.
|Capiaux GM, Budak-Alpdogan T, Alpdogan O, et al. (2004) Protection of hematopoietic stem cells from pemetrexed toxicity by retroviral gene transfer with a mutant dihydrofolate reductase-mutant thymidylate synthase fusion gene Cancer Gene Therapy. 11: 767-773|
|Capiaux GM, Budak-Alpdogan T, Takebe N, et al. (2003) Retroviral transduction of a mutant dihydrofolate reductase-thymidylate synthase fusion gene into murine marrow cells confers resistance to both methotrexate and 5-fluorouracil. Human Gene Therapy. 14: 435-46|
|Banerjee D, Mayer-Kuckuk P, Capiaux G, et al. (2002) Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase. Biochimica Et Biophysica Acta. 1587: 164-73|
|Sapse AM, Capiaux GM, Bertino JR. (2001) Examination of the reduced affinity of the thymidylate synthase G52S mutation for FdUMP by ab initio and semi-empirical studies. Molecular Medicine (Cambridge, Mass.). 7: 200-4|
|Banerjee D, Tong Y, Liu-Chen X, et al. (1999) Protection of bone marrow cells from toxicity of chemotherapeutic agents targeted toward thymidylate synthase by transfer of mutant forms of human thymidylate synthase cDNA. Progress in Experimental Tumor Research. 36: 107-14|
|Tong Y, Liu-Chen X, Ercikan-Abali EA, et al. (1998) Isolation and characterization of thymitaq (AG337) and 5-fluoro-2-deoxyuridylate-resistant mutants of human thymidylate synthase from ethyl methanesulfonate-exposed human sarcoma HT1080 cells. The Journal of Biological Chemistry. 273: 11611-8|